Clinician CONNECT

Cancer immunotherapy has emerged as a powerful treatment option characterized by durable remissions and tolerable side effects.

In recent years, an unprecedented number of immune-based therapeutic modalities have been approved in the first- and second-line as well as in the adjuvant setting across a growing number of malignancies. This influx of approvals has created a need to stay current on the latest recommendations for the appropriate application of immunotherapy.

Cancer Immunotherapy CONNECT, powered by SITC is your hub to participate in live and online educational opportunities to learn more about integrating cancer immunotherapy into your practice. Download a variety of resources in our library and connect with other clinicians in our online Community to learn more about the latest approvals, patient selection criteria, relevant biomarkers and immune-related adverse events.

Discussions

  • As you note, there are now many options for refractory metastatic RCC. They each have unique features which may make them more or less suitable for individual patients. I tend to use...

    2 people recommend this.
  • Although there is not clear evidence on sequencing or how to choose the best option for second line therapy in RCC. What do you think is important to consider, in terms of patient profile,...

    2 people recommend this.
  • Seb, The problem with reporting the conventional median overall survival is that it doesn't capture the tail of the curve, which is the place that each and every patient wants to end...

    2 people recommend this.

Resources

Jan 16, 2017 3:24 PM
Dan Chen MD, PhD from Stanford Medical Oncology and Genentech describes how our immune system detects cancer cells and how tumors get past our immune system by communicating with T cells through PD-L1, PD-1, and B7.1 interactions. This video animation helps viewers understand the effects of checkpoint...
Jan 16, 2017 3:19 PM
Created by Genentech, discover how a T-Cell traffic jam in tumors caused by the proteins PD-L1 and TIGIT is keeping the immune system from fighting off cancer and how it can be cleared.This article is intended as a resource for individuals who are being introduced to cancer immunotherapy and the key...
Jan 16, 2017 3:05 PM
Developed by Genentech, discover how results from clinical trials in cancer immunotherapy are being used in the research lab to try to understand why certain cancers do or do not respond to therapy. A closer look at the unconventional "bedside to bench" approach that is frequently being implemented...
Jan 16, 2017 2:30 PM
This program provides a snapshot of current research related to the identification of tumor antigens, characterization and isolation of specific T-cells for therapy, and discovery of neo-antigens all aimed at enabling the next generation of immunotherapies. Specific approaches driving immunotherapy...

Events


Featured Videos

NSCLC Immunotherapy - Advancing Hope™

Launched in July of 2016, SITC presents the newest in a series of videos focusing on immunotherapy for NSCLC patients, the NSCLC Immunotherapy: Advancing HopeTM video provides an overview of the building blocks of the immune system and immunotherapy, while also highlighting some* of the available FDA approved immunotherapy treatments and potential side effects, and the importance of clinical trials. View the video and then complete the companion activity for a free CME/CNE credit.

SITC – Leading the Cancer Immunotherapy Evolution

For more than 30 years SITC (Society for Immunotherapy of Cancer) has been fighting for treatment and a cure for cancer through research and collaboration. SITC members all over the world are leading the charge against cancer. We’re traveling the globe to meet these thought leaders and demonstrate the crucial work that they’re doing to impact advances in both the science and clinical application of immunotherapy.